Gilead Sciences, Inc.
NEWS
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
The approval marks the second approval for Trodelvy, which Gilead gained through its $21 billion acquisition of Immunomedics.
The agency granted full approval to Gilead Sciences’ Trodelvy (Sacituzumab govitecan-hziy) for adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more previous system therapies, at least one for metastatic disease.
Gilead CEO Daniel O’Day navigated the company through the turbulent waters of COVID-19 last year, pushing out the very first approved treatment for treatment of the virus. His reward? A $19 million take home.
John Martin, the chief executive officer who turned Gilead Sciences into a powerhouse company with treatments for hepatitis and HIV, died. He was 70 years old. A cause of death has not been announced.
As biopharma companies focus on efficiencies and close sites, jobs are getting lost. Here’s a look.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
JOBS
IN THE PRESS